Literature DB >> 33856598

MiR-34b-3p Impaired HUVECs Viability and Migration via Targeting PDK1 in an In Vitro Model of Gestational Diabetes Mellitus.

Feiluan Song1, Anli Cai2, Qianwen Ye1, Xiang Chen1, Lin Lin1, Xi Hao1.   

Abstract

Gestational diabetes mellitus (GDM) leads to poor pregnancy outcomes. The methods for GDM early diagnosis and treatment are still unknown. This study aimed to investigate the expression and diagnostic potential of miR-34b-3p in GDM patients and further analyzed the effects of miR-34b-3p on HUVECs viability and migration. The expression of miR-34b-3p was detected in HUVECs of GDM and normal pregnant women by qRT-PCR. Then the HUVECs were isolated from normal pregnant women. High glucose (HG) was used to treat the HUVECs to mimic the GDM in vitro. The cell viability and migration were determined by MTT, wound healing assay, and transwell assay. The interaction between miR-34b-3p and PDK1 was evaluated by luciferase activity assay. Our results showed that miR-34b-3p was up-regulated in HUVECs of GDM patients. Then the HUVECs were isolated from normal pregnant women and they were treated with HG to mimic the GDM in vitro. Interestingly, knockdown of miR-34b-3p restored the impairment of HG treatment-induced effects in HUVECs. More importantly, PDK1 was proved to be a potential target of miR-34b-3p. Finally, the rescue experiments confirmed that miR-34b-3p impaired cell viability and migration ability in HUVECs by targeting PDK1. These findings concluded that miR-34b-3p impaired HUVECs viability and migration in GDM by targeting PDK1, which might provide a novel perspective for the pathogenesis and underlying therapeutic target for GDM.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gestational diabetes mellitus; MiR-34b-3p; Migration; PDK1; Viability

Mesh:

Substances:

Year:  2021        PMID: 33856598     DOI: 10.1007/s10528-021-10064-9

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  31 in total

1.  Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass.

Authors:  Naoko Hashimoto; Yoshiaki Kido; Tohru Uchida; Shun-ichiro Asahara; Yutaka Shigeyama; Tomokazu Matsuda; Akihiko Takeda; Daisuke Tsuchihashi; Akihiko Nishizawa; Wataru Ogawa; Yoshito Fujimoto; Hitoshi Okamura; Karen C Arden; Pedro L Herrera; Tetsuo Noda; Masato Kasuga
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

2.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

Authors:  D R Alessi; S R James; C P Downes; A B Holmes; P R Gaffney; C B Reese; P Cohen
Journal:  Curr Biol       Date:  1997-04-01       Impact factor: 10.834

3.  Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia.

Authors:  Andrea Caporali; Marco Meloni; Christine Völlenkle; Desiree Bonci; Graciela B Sala-Newby; Roberta Addis; Gaia Spinetti; Sergio Losa; Rachel Masson; Andrew H Baker; Reuven Agami; Carlos le Sage; Gianluigi Condorelli; Paolo Madeddu; Fabio Martelli; Costanza Emanueli
Journal:  Circulation       Date:  2011-01-10       Impact factor: 29.690

4.  Activation of β1-adrenoceptors may not be involved in arrhythmogenesis in ischemic heart disease.

Authors:  Adriana D Adameova; Sukhwinder K Bhullar; Vijayan Elimban; Naranjan S Dhalla
Journal:  Rev Cardiovasc Med       Date:  2018-09-30       Impact factor: 2.930

5.  Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases.

Authors:  Rania Harfouche; Jean-Philippe Gratton; George D Yancopoulos; Michela Noseda; Aly Karsan; Sabah N A Hussain
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191

6.  Placenta changes in pregnancy with gestational diabetes.

Authors:  Antoine Edu; Cristina Teodorescu; Carmen Gabriela Dobjanschi; ZiŢa Zsuzsana Socol; Valeriu Teodorescu; Alexandru Matei; Dinu Florin Albu; Gabriela Radulian
Journal:  Rom J Morphol Embryol       Date:  2016       Impact factor: 1.033

Review 7.  Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes.

Authors:  A Ben-Haroush; Y Yogev; M Hod
Journal:  Diabet Med       Date:  2004-02       Impact factor: 4.359

8.  Transcriptome-Wide Identification and Characterization of Potato Circular RNAs in Response to Pectobacterium carotovorum Subspecies brasiliense Infection.

Authors:  Ran Zhou; Yongxing Zhu; Jiao Zhao; Zhengwu Fang; Shuping Wang; Junliang Yin; Zhaohui Chu; Dongfang Ma
Journal:  Int J Mol Sci       Date:  2017-12-27       Impact factor: 5.923

9.  5p and 3p Strands of miR-34 Family Members Have Differential Effects in Cell Proliferation, Migration, and Invasion in Cervical Cancer Cells.

Authors:  Sergio Córdova-Rivas; Ixamail Fraire-Soto; Andrea Mercado-Casas Torres; Luis Steven Servín-González; Angelica Judith Granados-López; Yamilé López-Hernández; Claudia Araceli Reyes-Estrada; Rosalinda Gutiérrez-Hernández; Julio Enrique Castañeda-Delgado; Leticia Ramírez-Hernández; José Antonio Varela-Silva; Jesús Adrián López
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

10.  MiR-34b-3p represses cell proliferation, cell cycle progression and cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting CDK4.

Authors:  Hongxiang Feng; Feixiang Ge; Lanfang Du; Zhenrong Zhang; Deruo Liu
Journal:  J Cell Mol Med       Date:  2019-06-14       Impact factor: 5.310

View more
  2 in total

1.  LncRNA RP11‑805J14.5 functions as a ceRNA to regulate CCND2 by sponging miR‑34b‑3p and miR‑139‑5p in lung adenocarcinoma.

Authors:  Huangkai Zhu; Xiang Xu; Enkuo Zheng; Junjun Ni; Xu Jiang; Minglei Yang; Guofang Zhao
Journal:  Oncol Rep       Date:  2022-07-22       Impact factor: 4.136

Review 2.  A Big Role for microRNAs in Gestational Diabetes Mellitus.

Authors:  Matladi Masete; Stephanie Dias; Nompumelelo Malaza; Sumaiya Adam; Carmen Pheiffer
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-25       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.